All In Biotech

Drug Trial Radar · NCT04786990

Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD

A Phase IV, Open-Label, Flexible-Dose Safety Trial Evaluating SPN-812 Administered With Psychostimulants in Children and Adolescents (6 to 17 Years of Age) With Attention-Deficit/Hyperactivity Disorder (ADHD)

Last checked: Nov 20, 2026Latest source record: May 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

96

Actual

Start

Jul 27, 2021

Primary completion

May 23, 2023

Study completion Jul 26, 2023

Sponsor

Lead sponsor
Supernus Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Mar 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This open label, flexible-dose study evaluating the safety and efficacy of SPN-812 administered with psychostimulants in children and adolescents (6 to 17 years of age) with Attention-Deficit/Hyperactivity Disorder (ADHD).

Conditions

  • Attention-Deficit/Hyperactivity Disorder (ADHD)

Interventions

  • SPN-812Drug

    Viloxazine extended-release capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events During 8 Weeks of Adjunct SPN-812 TreatmentTime frame: Weeks 1-8

Locations

17 sites in 2 countries. Site status is shown where the registry gives one.

  • Preferred Research Partners, Inc.

    Little Rock, Arkansas

  • NRC Research Institute

    Orange, California

  • Miami Clinical Research

    Miami, Florida

  • APG Research, LLC

    Orlando, Florida

  • Elite Clinical Trials

    Blackfoot, Idaho

  • Elite Clinical Trials

    Rexburg, Idaho

  • Qualmedica Research, LLC

    Evansville, Indiana

  • Psychiatric Associates Purehealth Medical Center

    Overland Park, Kansas

  • Midwest Research Group

    Saint Charles, Missouri

  • Alivation Research, LLC

    Lincoln, Nebraska

  • Center for Psychiatry and Behavioral Medicine

    Las Vegas, Nevada

  • SP Research, PLLC

    Oklahoma City, Oklahoma

  • Coastal Carolina Research Center

    North Charleston, South Carolina

  • Gadolin Research, LLC

    Beaumont, Texas

  • Family Psychiatry of The Woodlands

    The Woodlands, Texas

  • Northwest Clinical Research Center

    Bellevue, Washington

  • Barbara Diaz Hernandez MD Research, INC.

    San Juan, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.